Table 1 Baseline data of the included studies
From: A meta-analysis for vaccine protection rate of duck hepatitis a virus in mainland China in 2009–2021
Author(year) | article category | patent number | Outcome index | vaccine serotype | vaccine strain |
|---|---|---|---|---|---|
Qingxiong He(2010) | Paper | N | Protection efficiency/ serum antibody titer | 1 | XC-1 |
Xiaofei Zhang (2010) | Paper | N | Protection efficiency/ serum antibody titer | 1 | A66 |
Xuke Zhang (2010) | Patent | 201010273200.6 | Protection efficiency/ serum antibody titer | 1 | YC |
Shucai Fan (2012) | Patent | 201210414017.2 | Protection efficiency/ serum antibody titer | 1,3 | YB3,GD |
Anchun Cheng (2013) | Patent | 201310011872.3 | Protection efficiency/ serum antibody titer | 1 | CH60 |
Wenjun Liu (2014) | Patent | 201410834435.6 | Protection efficiency/ serum antibody titer | 1,3 | SH,FS |
Xiaofei Zhang (2015) | Patent | 201510006646.5 | Protection efficiency | 1,3 | HuB60,A66 |
Yang Song (2016) | Patent | 201610781512.5 | Protection efficiency/ serum antibody titer | 1,3 | SD,JS |
Siyuan Wei (2016) | Patent | 201610285099.3 | Protection efficiency | Unstated* | GS14 |
Jingling Su (2017) | Patent | 201710825604.3 | Protection efficiency | 3 | HB80 |
Jinqiang Zhang (2018) | Paper | N | Protection efficiency | 1,3 | YB3,GD |
Xingjian Wen (2019) | Patent | 201910551095.9 | Protection efficiency | 3 | ISA-A117C-C4334A |
Shenglei Chen (2020) | Patent | 202011299990.5 | Protection efficiency | 1,3 | LSE/QZE |
Fengyao Wu(2020) | Paper | N | Protection efficiency | 3 | SD70 |